Download PDF
Thromb Haemost 2017; 117(10): 1840
DOI: 10.1160/TH17-08-0573
Invited Editorial Focus
Schattauer GmbH

Accumulating data on rivaroxaban for venous thromboembolism in clinical practice

Sam Schulman
1   Thrombosis and Atherosclerosis Research Institute and McMaster University, Hamilton, Ontario, Canada
› Author Affiliations
Further Information

Publication History

Received: 20 August 2017

Accepted after major revision: 24 August 2017

Publication Date:
08 November 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Schulman S, Singer D, Ageno W. et al. NOACs for treatment of venous thromboembolism in clinical practice. Thromb Haemost 2017; 117: 1317-1325.
    Thieme ConnectPubMedSearch in Google Scholar
  • 2 Bauersachs R, Berkowitz SD, Brenner B. et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510.
    CrossrefPubMedSearch in Google Scholar
  • 3 Buller HR, Prins MH, Lensing AW. et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287-1297.
    CrossrefPubMedSearch in Google Scholar
  • 4 Coleman CI, Bunz TJ, Turpie AGG. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism. Thromb Haemost 2017; 117: 1841-1847.
    Thieme ConnectPubMedSearch in Google Scholar
  • 5 Sindet-Pedersen C, Pallisgaard JL, Staerk L. et al. Comparative safety and effectiveness of rivaroxaban versus vitamin K antagonists in patients with venous thromboembolism – A Danish nationwide registry-based study. Thromb Haemost 2017; 117: 1182-1191.
    Thieme ConnectPubMedSearch in Google Scholar